A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

Status:
Completed

Trial end date:
2017-01-05

Target enrollment:

Participant gender:

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett syndrome in children and adolescents.

Phase 2

Neuren Pharmaceuticals Limited

rettsyndrome.org

Pharmaceutical Solutions